<DOC>
	<DOC>NCT01297582</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety and tolerability of ONO-6950 across ascending single doses in healthy adult male and female subjects. The secondary objectives are to characterize the pharmacokinetic and pharmacodynamic profiles of ONO-6950 by measuring plasma concentrations of ONO-6950, pulmonary function, and potential cardiovascular effects. The tertiary objective of this study is to evaluate the effect of a meal upon the pharmacokinetic profile of ONO-6950.</brief_summary>
	<brief_title>Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy nonsmoking male or female subjects (1855 inclusive) Body mass index (BMI) of 1935kg/m2 (inclusive) For females, postmenopausal, nonlactating, and nonpregnant History or presence of clinical significant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ONO-6950</keyword>
	<keyword>Healthy Adult Subjects</keyword>
</DOC>